Endothelin Receptor Antagonists
"Endothelin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.
| Descriptor ID |
D065128
|
| MeSH Number(s) |
D27.505.519.364
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Endothelin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Endothelin Receptor Antagonists".
This graph shows the total number of publications written about "Endothelin Receptor Antagonists" by people in this website by year, and whether "Endothelin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 4 | 5 | 9 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Endothelin Receptor Antagonists" by people in Profiles.
-
Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulm Pharmacol Ther. 2021 08; 69:102035.
-
Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19. Med Hypotheses. 2021 May; 150:110564.
-
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer. Eur Urol Focus. 2020 Sep 15; 6(5):1086-1096.
-
Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe? J Heart Lung Transplant. 2020 07; 39(7):729-730.
-
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4).
-
Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019 07; 7(7):594-604.
-
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Eur Respir J. 2018 08; 52(2).
-
Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018 Dec 01; 272S:37-45.
-
The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review. Am J Cardiovasc Drugs. 2018 Apr; 18(2):93-102.
-
Highly Selective Endothelin-1 Receptor A Inhibition Prevents Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice. Respiration. 2018; 95(2):122-136.